← Leaderboards
Liya Ding
Roswell Park Cancer Institute Corp
$1,457,814
Attributed
$1,457,814
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $749.2K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,457,814 · 2
By mechanism
R37$1,011,702 · 1
R21$446,112 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Leigh Ellis$3,518,676
- Qianqian Zhu$1,921,800
- Robert Page Edwards$5,636,497
- Walter J Storkus$19,974,413
- Hua Zhao$6,386,020
Others in their field
Other Rising Stars on “Oncogenic”
- Timothy O'Connor · Rockefeller University$7,019,416
- Alexander Federation · Talus Bioscience, Inc.$4,098,558
- Jens Eickhoff · University Of Wisconsin-Madison$3,606,160
- Xu Chen · University Of California, San Francisco$3,581,285
- John D Gordan · University Of California, San Francisco$2,669,851
- Ricardo Mouro Pinto · Massachusetts General Hospital$2,559,051
Research focus
OncogenicSignal PathwayInhibitorNovel TherapeuticsPreclinical EvaluationResponseCombined Modality TherapyGenesMolecularNeoplastic CellPoly(Adp-Ribose) Polymerase InhibitorCancer CellReportingCancer PatientAtr GeneCoculture TechniquesDesignEffective TherapyIn VitroMalignant NeoplasmsCellsMouse ModelPhosphotransferasesSignal Transduction
Grant awards (4)
The Immunomodulatory Function of Cyclin E1 in Ovarian Cancer and Therapeutic Targeting$505,851
R37 · FY2025 · CA · contact PI
Combined inhibition of ATR and p110β as Therapy in PTEN-deficient Prostate Cancer$243,334
R21 · FY2025 · CA · contact PI
The Immunomodulatory Function of Cyclin E1 in Ovarian Cancer and Therapeutic Targeting$505,851
R37 · FY2024 · CA · contact PI
Combined inhibition of ATR and p110β as Therapy in PTEN-deficient Prostate Cancer$202,778
R21 · FY2024 · CA · contact PI